Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

TLPH

Talphera Inc

Apr 13 • 04:00PM ET

0.7784

+0.0178 2.34 %

Healthcare • Drug Manufacturers - Specialty & Generic • USA • NASD

Peers: LLY PFE MRK BMY JNJ GILD REGN AMGN VRTX BIIB

| Held by: VXF

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-0.36	Insider Own	27.45%	Shs Outstand	49.33M	Perf Week	6.47%
Market Cap	38.96M	Forward P/E	-	EPS next Y	-0.26	Insider Trans	3.26%	Shs Float	36.31M	Perf Month	-3.92%
Enterprise Value	25.08M	PEG	-	EPS next Q	-0.07	Inst Own	38.70%	Short Float	3.50%	Perf Quarter	-26.57%
Income	-14.29M	P/S	1298.70	EPS this Y	10.29%	Inst Trans	6.35%	Short Ratio	5.93	Perf Half Y	-38.71%
Sales	0.03M	P/B	2.25	EPS next Y	14.75%	ROA	-59.90%	Short Interest	1.27M	Perf YTD	-31.72%
Book/sh	0.35	P/C	1.91	EPS next 5Y	19.10%	ROE	-114.74%	52W High	1.57 -50.42%	Perf Year	55.68%
Cash/sh	0.41	P/FCF	-	EPS past 3/5Y	- 48.69%	ROIC	-60.72%	52W Low	0.38 104.84%	Perf 3Y	10.27%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -65.11%	Gross Margin	-	Volatility	11.12% 9.68%	Perf 5Y	-97.03%
Dividend TTM	-	EV/Sales	836.03	EPS Y/Y TTM	28.13%	Oper. Margin	-48157.14%	ATR (14)	0.07	Perf 10Y	-98.92%
Dividend Ex-Date	-	Quick Ratio	5.49	Sales Y/Y TTM	-90.04%	Profit Margin	-51035.71%	RSI (14)	47.38	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	5.49	EPS Q/Q	21.04%	SMA20	0.16%	Beta	0.65	Target Price	3.25
Payout	-	Debt/Eq	0.38	Sales Q/Q	-	SMA50	-5.76%	Rel Volume	0.49	Prev Close	0.76
Employees	12	LT Debt/Eq	0.38	Earnings	Mar 23 BMO	SMA200	-12.06%	Avg Volume	214.16K	Price	0.78
IPO	Feb 11, 2011	Option/Short	Yes / Yes	EPS/Sales Surpr.	20.00% -	Trades		Volume	104,860	Change	2.34%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-28-25	Initiated	Rodman & Renshaw	Buy	$4
Jul-20-20	Downgrade	Credit Suisse	Neutral → Underperform
Nov-11-19	Downgrade	Credit Suisse	Outperform → Neutral	$7 → $2
Aug-05-19	Resumed	Credit Suisse	Outperform
Jul-10-19	Resumed	Credit Suisse	Outperform
Apr-24-19	Resumed	B. Riley FBR	Buy	$6.50
Feb-15-19	Initiated	Credit Suisse	Outperform	$7
Oct-23-18	Initiated	B. Riley FBR	Buy	$9
Oct-13-17	Reiterated	RBC Capital Mkts	Outperform	$6 → $5
Oct-13-17	Downgrade	Jefferies	Buy → Hold
Jul-14-17	Resumed	Jefferies	Buy	$7
Sep-15-16	Reiterated	ROTH Capital	Buy	$11.25 → $15
Aug-05-16	Downgrade	Stifel	Buy → Hold
Oct-30-15	Upgrade	Jefferies	Hold → Buy
Oct-05-15	Reiterated	ROTH Capital	Buy	$8.50 → $10.50
Sep-02-15	Initiated	H.C. Wainwright	Buy	$8.50
Jul-10-15	Resumed	ROTH Capital	Buy	$7.50
May-06-15	Reiterated	Mizuho	Neutral	$5.50 → $3
May-05-15	Reiterated	RBC Capital Mkts	Outperform	$8 → $7
Mar-10-15	Reiterated	RBC Capital Mkts	Outperform	$12 → $8

Show Previous Ratings

Mar-25-26 08:30AM	Talphera Announces Two Abstracts Accepted for Presentation at AKI & CRRT 2026 (PR Newswire) +9.08%
Mar-23-26 08:44AM	Talphera: Q4 Earnings Snapshot (Associated Press Finance)
08:30AM	Talphera Announces Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update (PR Newswire)
Mar-18-26 04:05PM	Talphera to Host Virtual Investor & Analyst Event to Discuss Niyad for Use in Continuous Renal Replacement Therapy (CRRT), on March 23, 2026 (PR Newswire) -8.20%
Mar-02-26 08:30AM	Talphera Announces 50% Enrollment Milestone in Ongoing NEPHRO-CRRT Registrational Trial (PR Newswire)
12:00AM	Loading…
Nov-13-25 12:00AM	Talphera Inc (TLPH) Q3 2025 Earnings Call Highlights: Strategic Investments and Regulatory ... (GuruFocus.com) -18.60%
Nov-12-25 04:23PM	Talphera: Q3 Earnings Snapshot (Associated Press Finance)
04:05PM	Talphera Announces Third Quarter 2025 Financial Results and Provides Corporate Update (PR Newswire)
Nov-05-25 04:05PM	Talphera to Host Third Quarter Financial Results and Corporate Update Call and Webcast on Wednesday, November 12, 2025 (PR Newswire) -8.66%
Oct-21-25 08:30AM	Talphera Announces the Appointment of Joe Todisco to Board of Directors (PR Newswire)
Sep-08-25 08:30AM	Talphera Announces Private Placement Financing of up to $29 Million Priced At-the Market (PR Newswire) +49.13%
Aug-26-25 08:35AM	Talphera enrolls 17 patients in 70-patient pivotal NEPHRO CRRT clinical trial (TipRanks)
Aug-25-25 08:30AM	Talphera Announces Achievement of 17 Patient Enrollment Milestone in NEPHRO CRRT Pivotal Trial (PR Newswire) +16.62%
Aug-19-25 10:30AM	BC-Most Active Stocks (Associated Press Finance)
Aug-15-25 03:24AM	Talphera Inc (TLPH) Q2 2025 Earnings Call Highlights: Strategic Adjustments and Enrollment ... (GuruFocus.com)
04:15PM	Loading…
Aug-14-25 04:15PM	Talphera: Q2 Earnings Snapshot (Associated Press Finance)
04:05PM	Talphera Announces Second Quarter 2025 Financial Results and Provides Corporate Update (PR Newswire)
Aug-07-25 04:35PM	Talphera to Host Second Quarter Financial Results and Corporate Update Call and Webcast on Thursday, August 14, 2025 (PR Newswire)
May-15-25 03:16AM	Talphera Inc (TLPH) Q1 2025 Earnings Call Highlights: Strategic Cost Reductions and FDA ... (GuruFocus.com)
May-14-25 04:05PM	Talphera Announces First Quarter 2025 Financial Results and Provides Corporate Update (PR Newswire)
May-07-25 04:05PM	Talphera to Host First Quarter Financial Results and Corporate Update Call and Webcast on Wednesday, May 14, 2025 (PR Newswire) +6.97%
May-06-25 12:00PM	All You Need to Know About Talphera (TLPH) Rating Upgrade to Strong Buy (Zacks)
Apr-04-25 12:00PM	Talphera (TLPH) Upgraded to Buy: What Does It Mean for the Stock? (Zacks) -10.35%
Apr-01-25 03:03AM	Talphera Inc (TLPH) Q4 2024 Earnings Call Highlights: Strategic Moves and Financial Insights (GuruFocus.com) +7.07%
Mar-31-25 06:33PM	Talphera, Inc. (TLPH) Q4 2024 Earnings Call Transcript (Seeking Alpha) -15.53%
04:05PM	Talphera Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update (PR Newswire)
08:30AM	Talphera Announces Agreement with the FDA to Reduce the NEPHRO CRRT Study Size to 70 Patients From 166 and a Private Placement Financing Priced At-the Market of up to $14.8 Million (PR Newswire)
Mar-26-25 04:38PM	Talphera to Host Fourth Quarter and Full-Year 2024 Financial Results and Corporate Update Call and Webcast on Monday, March 31, 2025 (PR Newswire)
Jan-14-25 08:30AM	Talphera Announces Agreement with the FDA for Prior Approval Supplement Review to Reduce the Number of Patients in the NEPHRO CRRT Study (PR Newswire)
Nov-24-24 07:27PM	Ascentage Pharma Appoints Ms. Marina S. Bozilenko and Dr. Debra Yu as Independent Non-Executive Directors (PR Newswire)
02:14AM	Loading…
Nov-14-24 02:14AM	Talphera Inc (TLPH) Q3 2024 Earnings Call Highlights: Strategic Advances and Financial Challenges (GuruFocus.com) -25.61%
Nov-13-24 04:05PM	Talphera Announces Third Quarter 2024 Financial Results and Provides Corporate Update (PR Newswire)
Nov-06-24 04:05PM	Talphera to Host Third Quarter 2024 Financial Results and Corporate Update Call and Webcast on Wednesday, November 13, 2024 (PR Newswire)
Oct-08-24 04:54PM	Talphera to Participate in Fireside Chat at the 2024 Maxim Healthcare Virtual Summit (PR Newswire)
Sep-05-24 04:15PM	Talphera to Participate in the H.C. Wainwright 26th Annual Global Investment Conference (PR Newswire) +5.62%
Aug-19-24 08:30AM	Talphera Announces First Patient Enrolled in the Registrational Trial Evaluating Nafamostat for Anticoagulation of the Extracorporeal Circuit (PR Newswire)
Aug-14-24 04:01PM	Talphera Announces Second Quarter 2024 Financial Results and Provides Corporate Update (PR Newswire) -5.49%
Aug-05-24 04:05PM	Talphera to Host Second Quarter 2024 Financial Results and Corporate Update Call and Webcast on Wednesday, August 14, 2024 (PR Newswire)
Jun-26-24 07:41AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday (InvestorPlace) +6.02%
Jun-20-24 07:28AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday (InvestorPlace) +5.88%
May-20-24 05:25PM	Talphera Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
May-16-24 05:45PM	Talphera to Participate at A.G.P. Virtual Healthcare Conference (PR Newswire) -5.35% -6.09%
May-14-24 08:56PM	TLPH Stock Earnings: Talphera Beats EPS for Q1 2024 (InvestorPlace) +19.12%
04:05PM	Talphera Announces First Quarter 2024 Financial Results and Provides Corporate Update (PR Newswire)
May-02-24 04:15PM	Talphera to Host First Quarter 2024 Financial Results Call and Webcast on Tuesday, May 14, 2024 (PR Newswire)
Mar-06-24 09:53PM	TLPH Stock Earnings: Talphera Misses EPS, Beats Revenue for Q4 2023 (InvestorPlace) -10.63%
04:05PM	Talphera Announces Fourth Quarter 2023 Financial Results and Provides Corporate Update (PR Newswire)
Mar-01-24 07:30AM	Talphera Announces Reduction in Size of its Board of Directors from Ten to Seven Members (PR Newswire)
Feb-26-24 04:15PM	Talphera to Host Fourth Quarter and Full-Year 2023 Financial Results Call and Webcast on March 6, 2024 (PR Newswire)
Jan-18-24 08:30AM	Talphera Announces $26 Million Capital Commitment Through a Combination of a Non-Dilutive Royalty Monetization and Equity Offering (PR Newswire) +26.01%
Jan-09-24 09:05AM	AcelRx Announces Rebranding With Name Change to Talphera, Inc. (PR Newswire) +7.50%
Dec-12-23 08:30AM	AcelRx Pharmaceuticals Announces Publication of Study Evaluating Anticoagulation Practices for Continuous Renal Replacement Therapy in the United States (PR Newswire) -9.01%
Nov-09-23 11:06AM	AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) Q3 2023 Earnings Call Transcript (Insider Monkey) -11.34%
Nov-08-23 05:22PM	AcelRx Pharmaceuticals: Q3 Earnings Snapshot (Associated Press Finance)
04:05PM	AcelRx Reports Third Quarter 2023 Financial Results and Provides Corporate Update (PR Newswire)
Nov-07-23 04:05PM	AcelRx to Host KOL Panel Discussion on Current Anticoagulant Use in Dialysis and the Upcoming Niyad Clinical Study (PR Newswire)
Oct-26-23 04:30PM	AcelRx to Host Third Quarter 2023 Financial Results Call and Webcast on November 8, 2023 (PR Newswire)
Oct-03-23 08:30AM	AcelRx Receives IDE Approval for Niyad and Advances to a Single Registration Study (PR Newswire)
Sep-12-23 01:02PM	Insider Buying: CEO Vincent Angotti Acquires 10,000 Shares of AcelRx Pharmaceuticals Inc (GuruFocus.com) +12.80%
Sep-06-23 08:30AM	AcelRx Pharmaceuticals to Participate in the H.C. Wainwright Annual Investment Conference (PR Newswire)
Aug-22-23 05:30PM	What Makes AcelRx Pharmaceuticals (ACRX) a New Buy Stock (Zacks)
Aug-13-23 05:33AM	AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) Q2 2023 Earnings Call Transcript (Insider Monkey)
Aug-11-23 06:07AM	Q2 2023 AcelRx Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents)
Aug-10-23 05:30PM	AcelRx Pharmaceuticals (ACRX) Reports Q2 Loss, Tops Revenue Estimates (Zacks) -5.46%
04:20PM	AcelRx Pharmaceuticals: Q2 Earnings Snapshot (Associated Press Finance)
04:05PM	AcelRx Reports Second Quarter 2023 Financial Results and Provides Corporate Update (PR Newswire)
Jul-27-23 04:05PM	AcelRx to Host Second Quarter 2023 Financial Results Call and Webcast on August 10, 2023 (PR Newswire)
Jul-21-23 08:00AM	AcelRx Pharmaceuticals Announces Closing of Previously Announced Private Placement Priced At-The-Market Under Nasdaq Rules (PR Newswire)
Jul-18-23 08:00AM	AcelRx Pharmaceuticals Announces $10 Million Private Placement of Securities Priced At-The-Market Under Nasdaq Rules (PR Newswire)
May-10-23 06:25PM	AcelRx Pharmaceuticals (ACRX) Reports Break-Even Earnings for Q1 (Zacks) +10.88%
05:18PM	AcelRx Pharmaceuticals: Q1 Earnings Snapshot (AP Finance)
04:05PM	AcelRx Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate Update (PR Newswire)
May-04-23 10:00AM	Earnings Preview: Crinetics Pharmaceuticals, Inc. (CRNX) Q1 Earnings Expected to Decline (Zacks)
May-03-23 10:00AM	AcelRx Pharmaceuticals (ACRX) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release (Zacks)
Apr-27-23 04:05PM	AcelRx to Host First Quarter 2023 Financial Results Call and Webcast on May 10, 2023 (PR Newswire)
Apr-05-23 08:30AM	AcelRx Pharmaceuticals Announces Closing of Divestment of DSUVIA® to Alora Pharmaceuticals (PR Newswire)
Apr-04-23 12:30PM	AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) Q4 2022 Earnings Call Transcript (Insider Monkey)
Mar-30-23 06:15PM	AcelRx Pharmaceuticals (ACRX) Reports Q4 Loss, Lags Revenue Estimates (Zacks) -6.00%
04:05PM	AcelRx Pharmaceuticals Reports Full Year and Fourth Quarter 2022 Financial Results and Provides Corporate Update (PR Newswire)
Mar-29-23 10:13AM	12 Cheap Healthcare Stocks to Buy in 2023 (Insider Monkey)
Mar-21-23 04:05PM	AcelRx to Host Full Year and Fourth Quarter 2022 Financial Results Call and Webcast on March 30, 2023 (PR Newswire) +18.10% +5.68%
Mar-14-23 08:30AM	AcelRx Pharmaceuticals Announces Divestment of DSUVIA® to Alora Pharmaceuticals (PR Newswire) -21.05%
Mar-01-23 08:30AM	AcelRx Pharmaceuticals Announces Peer-Reviewed Publication On the Use of DSUVIA® For In-Office Rhinology Procedures (PR Newswire) -7.04%
Dec-29-22 06:02AM	AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) Q3 2022 Earnings Call Transcript (Insider Monkey) +7.58%
Dec-27-22 08:30AM	AcelRx Announces $7.5 Million Registered Direct Offering of Common Stock and Warrants to Purchase Common Stock (PR Newswire)
Dec-19-22 08:17AM	10 Cheapest Stocks With Biggest Upside (Insider Monkey) -7.95%
Dec-08-22 08:30AM	AcelRx Pharmaceuticals Announces European Peer-Reviewed Publication Supporting the Benefits of Sublingual Sufentanil Tablets For Post-Operative Pain Management in the Journal of Clinical Medicine (PR Newswire)
Nov-17-22 05:17AM	AcelRx Pharmaceuticals Third Quarter 2022 Earnings: EPS Beats Expectations, Revenues Lag (Simply Wall St.)
Nov-14-22 05:15PM	AcelRx Pharmaceuticals (ACRX) Reports Q3 Loss, Misses Revenue Estimates (Zacks) +17.96%
04:01PM	AcelRx Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update (PR Newswire)
Nov-03-22 08:30AM	AcelRx to Host Third Quarter 2022 Financial Results Call and Webcast on November 14, 2022 (PR Newswire)
Oct-31-22 08:30AM	AcelRx Pharmaceuticals Announces Presentation of a Large Cohort of Complex Plastic Surgery Procedures Performed with DSUVIA at Plastic Surgery The Meeting 2022 (PR Newswire)
Oct-27-22 08:30AM	AcelRx Pharmaceuticals Announces the European Launch of DZUVEO by its Partner, Aguettant (PR Newswire) -12.47%
Oct-26-22 08:30AM	AcelRx Pharmaceuticals Announces Presentation of Investigator-Initiated Trial Results Comparing AcelRx's Sufentanil Sublingual Tablet (SST) Versus Intravenous Opioids for Postoperative Pain at the ANESTHESIOLOGY® Annual Meeting 2022 (PR Newswire) -12.81%
Oct-25-22 04:42PM	AcelRx Pharmaceuticals Announces Reverse Stock Split (PR Newswire)
08:30AM	AcelRx Pharmaceuticals Announces ANESTHESIOLOGY® 2022 Annual Meeting Presentation on DSUVIA® for Battlefield Analgesia by the Uniformed Services University of the Health Sciences (PR Newswire)
Sep-06-22 04:30PM	AcelRx Pharmaceuticals to Participate in the H.C. Wainwright Annual Investment Conference (PR Newswire) -7.32% +5.74%
Aug-25-22 08:30AM	AcelRx Pharmaceuticals Announces a Second Abstract on DSUVIA® Accepted for Presentation at the ANESTHESIOLOGY® 2022 Annual Meeting (PR Newswire)
Aug-11-22 05:35PM	AcelRx Pharmaceuticals (ACRX) Reports Q2 Loss, Misses Revenue Estimates (Zacks) +33.02% -13.63%
04:01PM	AcelRx Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update (PR Newswire)

Talphera, Inc. engages in the development and commercialization of therapies used in medically supervised settings. The firm's portfolio includes Nafamostat, LTX-608, and Niyad. The company was founded by Thomas A. Schreck and Pamela Pierce Palmer on July 13, 2005 and is headquartered in San Mateo, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Angotti Vincent J.	CHIEF EXECUTIVE OFFICER	Mar 13 '26	Buy	0.59	213,310	125,000	800,705	Mar 25 07:57 PM
Angotti Vincent J.	CHIEF EXECUTIVE OFFICER	Feb 12 '26	Buy	0.81	105,364	85,587	586,954	Feb 20 08:28 PM
Aslam Shakil	Chief Medical Officer	Feb 12 '26	Buy	0.81	35,000	28,430	83,178	Feb 20 08:27 PM
Dasu Badri N	Chief Engineering Officer	Feb 12 '26	Buy	0.81	35,000	28,430	76,230	Feb 20 08:25 PM
ASADORIAN RAFFI	Chief Financial Officer	Feb 12 '26	Buy	0.81	45,000	36,554	91,256	Feb 20 08:23 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

TLPH

Talphera Inc

Upgrade your Finviz experience